-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptose Biosciences Reports 100% Response Rate for Tuspetinib Triple Therapy in Newly Diagnosed AML

Reuters·12/08/2025 12:16:04

Please log in to view news